LaNova Medicines Entered into an Exclusive License Agreement with AstraZeneca for LM-305 to Treat Multiple Myeloma
- LaNova Medicines will receive an up front and near-term fees of ~$55M and is eligible to receive additional development and commercial milestones of ~$545M along with royalties on net sales globally
- AstraZeneca to get an exclusive license globally to research, develop, and commercialize LM-305, a pre-clinical stage ADC targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D)
- The collaboration focuses on discovering and developing innovative therapies in ADC and Immuno-Oncology. LM-305 strengthens AstraZeneca's position in ADCs and adds to the expanding haematology pipeline providing clinical outcomes for patients living with blood cancers
Ref: PRNewswire | Image: AstraZeneca
Related News:- AstraZeneca’s Ultomiris (ravulizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder in EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].